# EDGAR Filing Document

**Accession Number:** 0001029142
**File Stem:** 0001628280-25-058985
**Filing Date:** 2025-12
**Character Count:** 9101
**Document Hash:** 86c637806dc47e29beddaa15a644b612
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-25-058985.hdr.sgml**: 20251229

**ACCESSION NUMBER**: 0001628280-25-058985

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251223

**FILED AS OF DATE**: 20251229

**DATE AS OF CHANGE**: 20251229

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Novack David F
- **CENTRAL INDEX KEY:** 0001573072

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-34207
- **FILM NUMBER:** 251609247

**MAIL ADDRESS:**
- **STREET 1:** 39 YORKSHIRE DR
- **CITY:** OAKLAND
- **STATE:** CA
- **ZIP:** 94618
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** DYNAVAX TECHNOLOGIES CORP
- **CENTRAL INDEX KEY:** 0001029142
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 330728374
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 2100 POWELL STREET
- **STREET 2:** SUITE 720
- **CITY:** EMERYVILLE
- **STATE:** CA
- **ZIP:** 94608
- **BUSINESS PHONE:** 5108485100

**MAIL ADDRESS:**
- **STREET 1:** 2100 POWELL STREET
- **STREET 2:** SUITE 720
- **CITY:** EMERYVILLE
- **STATE:** CA
- **ZIP:** 94608

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Novack David F<br><sub>(Last) (First) (Middle)</sub><br>C/O DYNAVAX TECHNOLOGIES<br>2100 POWELL STREET, SUITE 720<br><sub>(Street)</sub><br>EMERYVILLE, CA 94608<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-12-23 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_President & COO_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>DYNAVAX TECHNOLOGIES CORP [ DVAX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2025-12-23 |  | A<sup>(1)</sup> |  | 60625 | A | <sup>(2)</sup> | 70043<sup>(3)</sup> | D |  |
| Common Stock | 2025-12-23 |  | M<sup>(1)</sup> |  | 22620 | A | <sup>(4)</sup> | 92663<sup>(3)</sup> | D |  |
| Common Stock | 2025-12-23 |  | M<sup>(1)</sup> |  | 18788 | A | <sup>(4)</sup> | 111451<sup>(3)</sup> | D |  |
| Common Stock | 2025-12-24 |  | M<sup>(5)</sup> |  | 20000 | A | $6.805 | 131451<sup>(3)</sup> | D |  |
| Common Stock | 2025-12-24 |  | M<sup>(5)</sup> |  | 10000 | A | $10.47 | 141451<sup>(3)</sup> | D |  |
| Common Stock | 2025-12-24 |  | S<sup>(5)</sup> |  | 30000 | D | $15.49 | 111451<sup>(3)</sup> | D |  |
| Common Stock | 2025-12-24 |  | F |  | 48107<sup>(6)</sup> | D | $15.38 | 63344<sup>(3)</sup> | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Restricted Stock Unit | <sup>(7)</sup> | 2025-12-23 |  | M<sup>(1)</sup> |  |  | 22620 | <sup>(7)</sup> | <sup>(7)</sup> | Common Stock | 22620 | <sup>(4)</sup> | 22620 | D |  |
| Restricted Stock Unit | <sup>(8)</sup> | 2025-12-23 |  | M<sup>(1)</sup> |  |  | 18788 | <sup>(8)</sup> | <sup>(8)</sup> | Common Stock | 18788 | <sup>(4)</sup> | 37576 | D |  |
| Stock Option (Right to Buy) | $6.805 | 2025-12-24 |  | M<sup>(5)</sup> |  |  | 20000 | <sup>(9)</sup> | 2026-12-15 | Common Stock | 20000 | <sup>(10)</sup> | 166528 | D |  |
| Stock Option (Right to Buy) | $10.47 | 2025-12-24 |  | M<sup>(5)</sup> |  |  | 10000 | <sup>(9)</sup> | 2026-02-21 | Common Stock | 10000 | <sup>(10)</sup> | 85655 | D |  |

---

### Footnotes:

(1) On December 23, 2025 (the "Effective Date"), in connection with the execution of an Agreement and Plan of Merger dated as of the Effective Date (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger
Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent, the Board of Directors of the Issuer approved acceleration of vesting of certain performance-based restricted stock units ("PSUs") and restricted stock units ("RSUs") previously granted to the
Reporting Person, effective as of the Effective Date.

(2) Represents PSUs previously granted to the Reporting Person that vest based on how the Issuer's total stockholder return compares to the total stockholder return of an indexed group of companies ("rTSR") over a performance period ending on December 31, 2025. Each
PSU represents a contingent right to receive one share of common stock. On the Effective Date, the Board of Directors of the Issuer determined that these PSUs (which represent 125% of the target number of PSUs) were earned according to achievement of the rTSRperformance condition over a shortened performance period, with the Issuer's total stockholder return determined based on the amount payable for a share of the Issuer's common stock pursuant to the Merger Agreement ($15.50), and approved such acceleration of vestingof the earned PSUs.

(3) Includes 1,340 shares purchased through the Issuer's Employee Stock Purchase Plan on August 15, 2025.

(4) Each RSU represents a contingent right to receive one share of the Issuer's common stock.

(5) The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 6, 2024.

(6) Shares withheld by the Issuer to satisfy tax withholding requirements on vesting of PSUs and RSUs.

(7) The RSUs were granted on February 15, 2024, and were originally scheduled to vest over three years, with 1/3 vesting on each anniversary of February 15, 2024.

(8) The RSUs were granted on February 13, 2025, and were originally scheduled to vest over three years, with 1/3 vesting on each anniversary of February 13, 2025.

(9) Fully vested.

(10) Not applicable.

**Signature:** David F. Novack, by /s/ Trevor Dutcher, Attorney-in-Fact  
**Date:** 2025-12-29

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**